LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

被引：0
|
作者：
Kupas, K. [1 ]
Kaspar, I. [1 ]
Baecke, V. [2 ]
Weisel, K. [3 ]
机构：
[1] Bristol Myers Squibb, Munich, Germany
[2] Ecker Ecker GmbH, Hamburg, Germany
[3] Univ Tubingen, Tubingen, Germany
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1256
引用
收藏
页码：514 / 515
页数：2
相关论文
共 50 条
  • [41] Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
    Kropff, M
    Bisping, G
    Liebisch, P
    Sezer, O
    Einsele, H
    Straka, C
    Kroeger, N
    Metzner, B
    Engelhardt, M
    Lang, N
    Hentrich, M
    Wolf, H
    von Schilling, C
    Salwender, H
    Berdel, WE
    Kienast, J
    BLOOD, 2005, 106 (11) : 716A - 716A
  • [42] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Richardson, PG
    Sonneveld, P
    Schuster, MW
    Irwin, D
    Stadtmauer, EA
    Facon, T
    Harousseau, JL
    Ben-Yehuda, D
    Lonial, S
    Goldschmidt, H
    Reece, D
    San-Miguel, JF
    Bladé, J
    Boccadoro, M
    Cavenagh, J
    Dalton, WS
    Boral, AL
    Esseltine, DL
    Porter, JB
    Schenkein, D
    Anderson, KC
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24): : 2487 - 2498
  • [43] A phase lb multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed multiple myeloma - preliminary results
    Niesvizky, R.
    Wang, M.
    Bensinger, B.
    Vallone, M.
    Gutierrez, A. A.
    Kauffman, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 569 - 569
  • [44] Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM)
    Bensinger, W.
    Wang, M.
    Orlowski, R. Z.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrall, N. Y.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/ REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE STUDY
    Firatli-Tuglular, T.
    Noyan-Atalay, F.
    Eser, A.
    Toptas, T.
    Pepedil, F.
    Kaygusuz-Atagunduz, I.
    Adiguzel, C.
    HAEMATOLOGICA, 2013, 98 : 614 - 615
  • [46] Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome
    Cai, Qian-Qian
    Wang, Chen
    Cao, Xin-Xin
    Cai, Hao
    Zhou, Dao-Bin
    Li, Jian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 325 - 330
  • [47] Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?
    Robert Z Orlowski
    Nature Clinical Practice Oncology, 2006, 3 : 16 - 17
  • [48] Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?
    Orlowski, RZ
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 16 - 17
  • [49] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey S. Y.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth C.
    BLOOD, 2022, 140
  • [50] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
    Richardson, Paul
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
12345